<DOC>
	<DOCNO>NCT00412867</DOCNO>
	<brief_summary>The purpose study confirm efficacy safety intravenously administer alteplase patient acute ischemic stroke base rate recanalization assess magnetic resonance angiography ( MRA ) , rate patient modify Rankin Scale ( mRS ) score 0-1 , incidence symptomatic intracranial hemorrhage ( sICH ) , comparison data report current literature .</brief_summary>
	<brief_title>Post-marketing Clinical Study Alteplase Acute Ischemic Stroke （Japan Alteplase Clinical Trial Ⅱ：J-ACT Ⅱ）</brief_title>
	<detailed_description />
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Tissue Plasminogen Activator</mesh_term>
	<criteria>Patients acute ischemic stroke within 3 hour onset , clearly defined time onset . Patients reveal occlusion one side middle cerebral artery ( M1 M2 portion ) MRA start treatment . Patients consent obtain either legally acceptable representative write form . Patients light neurological symptom ( NIHSS score &lt; = 4 ) rapidly improve symptom start treatment . Patients serious neurological disorder ( NIHSS score &gt; = 23 ) , serious consciousness disorder ( Japan Coma Scale score &gt; = 100 ) start treatment . Patients functional disorder ( mRS score &gt; = 2 ) stroke onset . Patients administer drug allow administer concomitantly alteplase ( thrombolytic agent ) stroke onset . Patients reveal extensive early ischemic change ( Alberta Stroke Program Early CT score &lt; = 6 ) compute tomography ( CT ) treatment . Patients reveal obvious occlusion blood vessel except middle cerebral artery MRA treatment . Patients forbidden undergo magnetic resonance imaging ( MRI ) . Patients define cerebral hemorrhage subarachnoid hemorrhage ( SAH ) CT treatment . Patients whose symptom suggest SAH . Patients hemorrhage ( gastrointestinal hemorrhage , urinary hemorrhage , retroperitoneal hemorrhage , hemoptysis ) . Patients platelet count 100,000/mm3 . Patients fast blood glucose level &lt; 50 mg/dL &gt; 400 mg/dL . Patients whose activated partial thromboplastin time ( APTT ) prolong due heparin administration within 48 hour stroke onset . Patients administer oral anticoagulant value international normalized ratio prothrombin time ( PTINR ) &gt; 1.7 . Patients systolic blood pressure &gt; 185 mmHg diastolic blood pressure &gt; 110 mmHg . Patients need antihypertensive therapy ( e.g . continuous infusion antihypertensive drug etc . ) low blood pressure limit precede article . Patients history intracranial hemorrhage , disease consider increase risk intracranial hemorrhage intracranial tumor , cerebral aneurysm , intracranial arteriovenous malformation , etc . Patients history stroke within 3 month onset . Patients operate injured head spinal cord within 3 month onset . Patients history gastrointestinal urinary tract hemorrhage within 21 day onset . Patients major surgery serious trauma ( except head spinal cord trauma ) within 14 day onset . Patients history organ biopsy , arterial puncture , lumbar puncture within 10 day onset . Patients severe hepatic dysfunction severe renal dysfunction . Patients acute pancreatitis . Patients seizure onset stroke . Patients history hypersensitivity protein preparation . Patients lactate , pregnant , probably pregnant , menstruate . Patients malignant tumor . Patients acute myocardial infarction ( AMI ) pericarditis AMI . Patients concurrent infectious endocarditis , moyamoya disease ( Willis circle occlusion syndrome ) , aortic dissection , neck trauma , etc . Patients strong suspicion ischemic cerebrovascular disorder cause nonthrombotic occlusion hemodynamic condition . Patients judge difficult monitor 3 month physician . Patients participate clinical trial last 3 month . In addition exclusion criterion , patient judge inadequate participate study physician .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Cerebral Infarction</keyword>
	<keyword>acute ischemic stroke</keyword>
	<keyword>Brain ischemia</keyword>
</DOC>